# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
– The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications ––...
- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - Overall Response Rate (ORR) of 3...
SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate...
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of P...
SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate...